2013
First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.
Camidge D, Bazhenova L, Salgia R, Weiss G, Langer C, Shaw A, Narasimhan N, Dorer D, Rivera V, Zhang J, Clackson T, Haluska F, Gettinger S. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results. Journal Of Clinical Oncology 2013, 31: 8031-8031. DOI: 10.1200/jco.2013.31.15_suppl.8031.Peer-Reviewed Original ResearchTyrosine kinase inhibitorsAdverse eventsAdvanced malignanciesCommon grade 3/4 treatment-related adverse eventsGrade 3/4 treatment-related adverse eventsEGFR-TKI resistant NSCLCNon-small cell lung cancerTreatment-related adverse eventsALK tyrosine kinase inhibitorsPhase I/IINovel tyrosine kinase inhibitorEGFR tyrosine kinase inhibitorsDose finding phaseGrade 4 dyspneaTKI-resistant NSCLCPhase II doseFollow-up scanCell lung cancerDose-finding studyAge 60 yrAnaplastic lymphoma kinaseAnti-tumor activityEpidermal growth factor receptorGrowth factor receptorStable disease
2012
Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC).
Gunturu K, Thumar J, Hochster H, Stein S, Yao X, Cong X, Hahn C, Kaley K, Lacy J. Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). Journal Of Clinical Oncology 2012, 30: 330-330. DOI: 10.1200/jco.2012.30.4_suppl.330.Peer-Reviewed Original ResearchAdvanced pancreatic cancerPancreatic cancerProphylactic pegfilgrastimMetastatic PCFull dosesAdvanced unresectable pancreatic cancerECOG PS 0Efficacy of FOLFIRINOXRelative dose intensityUnresectable pancreatic cancerYale Cancer CenterMetastatic pancreatic cancerSingle institution experienceWarrants further evaluationCycle 1Age 60 yrEquivalent response ratesDose attenuationChemotherapy 5Evaluable ptsFebrile neutropeniaUnderwent resectionDose intensitySurgical resectionUnacceptable toxicity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply